ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2013-09-26
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 70
- Registration Number
- NCT00282568
A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-01-26
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 70
- Registration Number
- NCT00282243
A Study to Evaluate the Safety and Efficacy of Prograf/FK778 and Prograf/MMF in de Novo Kidney Transplant Recipients
Phase 2
Terminated
- Conditions
- First Posted Date
- 2006-01-26
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 150
- Registration Number
- NCT00282230
A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-01-26
- Last Posted Date
- 2013-10-17
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 19
- Registration Number
- NCT00282256
A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 29
- Registration Number
- NCT00281541
Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2008-04-03
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 254
- Registration Number
- NCT00281554
A Study of Ramosetron Plus DX, Dexamethasone, Compared to Granisetron Plus DX for the Prevention of Vomiting and Nausea
- First Posted Date
- 2006-01-05
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 287
- Registration Number
- NCT00272285
A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-11-23
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Astellas Pharma Inc
- Registration Number
- NCT00257478
Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2014-08-26
- Lead Sponsor
- Astellas Pharma Inc
- Registration Number
- NCT00239252
Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2007-10-22
- Lead Sponsor
- Astellas Pharma Inc
- Registration Number
- NCT00239265
© Copyright 2024. All Rights Reserved by MedPath